Name | N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-pyrrolidin-1-ylpropan-2-yl]hexadecanamide |
---|---|
Synonyms |
D-threo-1-(3',4'-Ethylenedioxy)phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol
Hexadecanamide,N-[(1R,2R)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl] |
Description | EtDO-P4 is a nanomolar inhibitor of glycosphingolipid (GSL) synthesis. EtDO-P4 suppresses activation of the EGFR-induced ERK pathway and various receptor tyrosine kinases (RTKs). EtDO-P4 can be used for various types of cancer, including Burkitt’s lymphoma[1]. |
---|---|
Related Catalog | |
References |
Density | 1.05g/cm3 |
---|---|
Boiling Point | 684.419ºC at 760 mmHg |
Molecular Formula | C31H52N2O4 |
Molecular Weight | 516.75600 |
Flash Point | 367.723ºC |
Exact Mass | 516.39300 |
PSA | 71.03000 |
LogP | 6.88190 |
Vapour Pressure | 0mmHg at 25°C |
Index of Refraction | 1.524 |